ST Pharm
Seoul, South Korea
Compare Oligo/ASO CDMOs in Asia
Compare Oligo/ASO CDMOs in South Korea
Compare mRNA/LNP CDMOs in Asia
Compare mRNA/LNP CDMOs in South Korea
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (18)
○ EMA GMP
○ MHRA GMP
Quick Facts: ST Pharm
- Signal Score
- 59.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Seoul, South Korea
- Modalities
- Oligonucleotide, mRNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About ST Pharm
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: Seoul, KR
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Sites: Seoul, KR
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals18 articles (not scored)
1 manufacturing site: Seoul, KR
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 18 articles
Company announcements, not verified evidence. They do not change any score.
Dong-A ST and ST Pharm log Q3 sales, profit gains in South Korea - Chosunbiz
Dong-A ST and ST Pharm log Q3 sales, profit gains in South Korea Chosunbiz
ST Pharm, Which Received Equipment and Technology Support from Roche, Sets Sights on Major RNA Contract Manufacturing Orders - BigGo Finance
ST Pharm, Which Received Equipment and Technology Support from Roche, Sets Sights on Major RNA Contract Manufacturing Orders BigGo Finance
Roche ties help Korea’s ST Pharm pursue major RNA CDMO wins - Chosunbiz
Roche ties help Korea’s ST Pharm pursue major RNA CDMO wins Chosunbiz
ST Pharm pitches expanded oligonucleotide capacity to global drugmakers at CPHI - Korea Biomedical Review
ST Pharm pitches expanded oligonucleotide capacity to global drugmakers at CPHI Korea Biomedical Review
ST Pharm Seeks New Oligonucleotide CDMO Contracts at CPHI 2026 - 아시아경제
ST Pharm Seeks New Oligonucleotide CDMO Contracts at CPHI 2026 아시아경제
ST Pharm First-Quarter Operating Profit Surges Tenfold - thelec.net
ST Pharm First-Quarter Operating Profit Surges Tenfold thelec.net
Dong-A group's Q1 sales rise as ST Pharm, Dong-A ST profits climb - koreabiomed.com
Dong-A group's Q1 sales rise as ST Pharm, Dong-A ST profits climb koreabiomed.com
ST Pharm Secures Japanese Patent for Key LNP Material 'STP1244' - 아시아경제
ST Pharm Secures Japanese Patent for Key LNP Material 'STP1244' - The Asia Business Daily 아시아경제
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands - 서울경제신문
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands Seoul Economic Daily
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands - Seoul Economic Daily
ST Pharm Poised for Order Surge as RNA Therapeutics Market Expands Seoul Economic Daily
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract - Businesskorea
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract Businesskorea
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant - 더바이오
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant 더바이오
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ - Chosunbiz
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ Chosunbiz
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date - 아시아경제
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date 아시아경제
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine - koreabiomed.com
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine koreabiomed.com
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples - 아시아경제
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples 아시아경제
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ - Chosunbiz
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ biz.chosun.com
Korea’s pharma ramps up capacity to win global orders amid pricing shifts - CHOSUNBIZ - biz.chosun.com
Korea’s pharma ramps up capacity to win global orders amid pricing shifts - CHOSUNBIZ Chosunbiz
Frequently Asked Questions About ST Pharm
What is ST Pharm's CDMO Signal Score?
ST Pharm has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating ST Pharm for a manufacturing program?
Use the free AI matchmaker to compare ST Pharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.5
mRNA, Oligonucleotide, Biologics
TriLink BioTechnologies
San Diego, CA
Signal Score: 63.0
mRNA, Oligonucleotide
Compare ST Pharm with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.